Clinical Trials Logo
  1. Home
  2. Malignant Neoplasm of Stomach
  3. NCT02528110

Radical Gastrectomy and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer

Malignant Neoplasm of Stomach Clinical Trial

Official title:
A Phase II Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Locally Advanced Gastric Cancer During Radical Gastrectomy

Clinical Trial Summary

The efficacy of HIPEC in prevention of local recurrence, distant metastasis or peritoneal metastasis in locally advanced gastric cancer is not definite. The hypothesis of the trial is that radical gastrectomy plus HIPEC is superior to only radical gastrectomy in terms of overall survival.

Clinical Trial Description

To determine the efficacy of HIPEC in the treatment of locally advanced gastric cancer, patients are randomized into HIPEC group and control group. In HIPEC group, the patients undergo radical gastrectomy with D2 lymphadenectomy and HIPEC with paclitaxel and 5-Fu. Patients in the control group just undergo radical gastrectomy with D2 lymphadenectomy. Patients in both groups receive 6 cycles of postoperative chemotherapy (SOX or XELOX) and are followed up for 5 years or until death.

The trial is designed as a prospective, randomized, open, multicenter and parallel group study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02528110
Study type Interventional
Source Wuhan University
Contact
Status Completed
Phase Phase 2
Start date August 2015
Completion date March 10, 2020
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01727908 - Screening for Familial Gastric Cancer in First Degree Relatives N/A
Completed NCT02337673 - Screening of Postoperative Pulmonary Complications by Electrical Impedance Tomography
Completed NCT02158988 - Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis Phase 3
Recruiting NCT01642953 - Early Recovery After Gastric Cancer Surgery Phase 2
Active, not recruiting NCT02205047 - Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma Phase 2
Recruiting NCT02381847 - Radical Gastrectomy With/Without HIPEC in Advanced Gastric Cancer Patients Phase 3
Completed NCT01443065 - MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma Phase 2
Completed NCT01758965 - Surgicel® Fibrillar for Delayed Bleeding After ESD N/A
Completed NCT01187212 - Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATE Phase 2
Recruiting NCT05880667 - Adaptive Radiation for Abdominopelvic Metastases Phase 1
Recruiting NCT04345770 - Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer Phase 2